A phase three clinical trial is being conducted here to evaluate the safety and efficacy of a new quadrivalent dengue vaccine ...

Biotech company CRISPR Therapeutics has a market cap of around $5 billion, but it has the potential to be much more valuable ...

As the global obesity medication market skyrockets, South Korean pharmaceuticals are rushing to develop national obesity ...

Investors look at many variables when deciding which stocks to buy, including a company's industry. If an industry is exhibiting high growth, stocks in that sector can gain value. It' ...

These capabilities illustrate the multifaceted promise of AI: speeding up scientific discovery, improving patient outcomes, ...

Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for its Phase 2a ...

The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The rapid lateral flow assay from Lumos Diagnostics distinguishes bacterial and nonbacterial respiratory infections using a drop of blood.

Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...